Literature DB >> 10571209

The immunohistochemical expression of DNA-PKCS and Ku (p70/p80) in head and neck cancers: relationships with radiosensitivity.

T Björk-Eriksson1, C West, A Nilsson, B Magnusson, M Svensson, E Karlsson, N Slevin, R Lewensohn, C Mercke.   

Abstract

PURPOSE: The DNA-PK complex is one of the major pathways by which mammalian cells respond to DNA double-strand breaks induced by ionizing radiation. This study evaluated the relationship between the immunohistochemical expression of the individual components of DNA-PK and cellular radiosensitivity in head and neck cancers. METHODS AND MATERIALS: Biopsies from patients with previously untreated squamous cell carcinomas of the head and neck were assessed for inherent tumor radiosensitivity measured as the surviving fraction at 2 Gy (SF2) using a soft agar clonogenic assay. Paraffin-embedded tumor material from 64 successfully grown specimens was immunohistochemically stained for expression of DNA-PKcs and Ku (p70/p80). The same tumor material was previously analyzed for the immunohistochemical expression of p53.
RESULTS: A significant correlation was found between the degree of expression of DNA-PKcs and Ku (p70/p80) (r = 0.55, p<0.001). There were no overall significant differences in the levels of expression of DNA-PKcs and Ku (p70/p80) in tumors from patients of either sex, different sites, histologies, and stages. No relationship was found between SF2 and the expression of either DNA-PKcs (r = 0.22, p = 0.081) or Ku (p70/p80) (r = 0.064, p = 0.62). Comparison with previous immunohistochemical characterization showed no significant correlations between the expression levels of p53 and either DNA-PKcs (r = 0.093, p = 0.46) or Ku (p70/p80) (r = -0.17, p = 0.17).
CONCLUSIONS: This study suggests that determining the immunohistochemical expression of DNA-PK in head and neck cancers from multiple sites does not have a role as a predictive assay of tumor in vitro radiosensitivity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571209     DOI: 10.1016/s0360-3016(99)00268-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Prognostic significance of ataxia-telangiectasia mutated, DNA-dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86-kD subunit expression in patients with nonsmall cell lung cancer.

Authors:  Jinliang Xing; Xifeng Wu; Ara A Vaporciyan; Margaret R Spitz; Jian Gu
Journal:  Cancer       Date:  2008-06-15       Impact factor: 6.860

2.  Expression of DNA damage response proteins and complete remission after radiotherapy of stage IB-IIA of cervical cancer.

Authors:  C Beskow; L Kanter; A Holgersson; B Nilsson; B Frankendal; E Avall-Lundqvist; R Lewensohn
Journal:  Br J Cancer       Date:  2006-06-05       Impact factor: 7.640

3.  Expression of Ku70 correlates with survival in carcinoma of the cervix.

Authors:  C R Wilson; S E Davidson; G P Margison; S P Jackson; J H Hendry; C M West
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

4.  Identification of DNA-PKcs as a primary resistance factor of TIC10 in hepatocellular carcinoma cells.

Authors:  Long Cheng; Yuan-Yuan Liu; Pei-Hua Lu; Yi Peng; Qiang Yuan; Xin-Shi Gu; Yong Jin; Min-Bin Chen; Xu-Ming Bai
Journal:  Oncotarget       Date:  2017-04-25

5.  Identification of DNA-PKcs as a primary resistance factor of salinomycin in osteosarcoma cells.

Authors:  Yun-Fang Zhen; Song-Tao Li; Yun-Rong Zhu; Xiao-Dong Wang; Xiao-Zhong Zhou; Lun-Qing Zhu
Journal:  Oncotarget       Date:  2016-11-29

6.  DNA‑PKcs inhibitor increases the sensitivity of gastric cancer cells to radiotherapy.

Authors:  Wei Geng; Dalong Tian; Qiang Wang; Shunlin Shan; Jianwei Zhou; Wenxia Xu; Husheng Shan
Journal:  Oncol Rep       Date:  2019-06-06       Impact factor: 3.906

7.  KU-0060648 inhibits hepatocellular carcinoma cells through DNA-PKcs-dependent and DNA-PKcs-independent mechanisms.

Authors:  Min-Bin Chen; Zhen-Tao Zhou; Lan Yang; Mu-Xin Wei; Min Tang; Ting-Yan Ruan; Jun-Ying Xu; Xiao-Zhong Zhou; Gang Chen; Pei-Hua Lu
Journal:  Oncotarget       Date:  2016-03-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.